BTR Capital Management Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 1.3% in the third quarter, Holdings Channel reports. The fund owned 94,737 shares of the company’s stock after selling 1,265 shares during the period. Johnson & Johnson accounts for approximately 2.5% of BTR Capital Management Inc.’s investment portfolio, making the stock its 10th largest holding. BTR Capital Management Inc.’s holdings in Johnson & Johnson were worth $12,317,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. OLD Point Trust & Financial Services N A increased its holdings in shares of Johnson & Johnson by 2.2% during the 2nd quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after buying an additional 1,321 shares during the last quarter. Welch & Forbes LLC increased its holdings in shares of Johnson & Johnson by 0.9% during the 2nd quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock worth $95,028,000 after buying an additional 6,730 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Johnson & Johnson by 0.5% during the 2nd quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after buying an additional 3,533 shares during the last quarter. Oliver Luxxe Assets LLC increased its holdings in shares of Johnson & Johnson by 12.7% during the 2nd quarter. Oliver Luxxe Assets LLC now owns 17,538 shares of the company’s stock worth $2,320,000 after buying an additional 1,972 shares during the last quarter. Finally, Sitrin Capital Management LLC increased its holdings in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Sitrin Capital Management LLC now owns 48,986 shares of the company’s stock worth $6,480,000 after buying an additional 792 shares during the last quarter. Institutional investors own 65.70% of the company’s stock.

Johnson & Johnson (NYSE JNJ) opened at $145.76 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The firm has a market cap of $391,590.00, a P/E ratio of 25.31, a P/E/G ratio of 2.67 and a beta of 0.80. Johnson & Johnson has a 1 year low of $110.76 and a 1 year high of $146.42.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter last year, the company posted $1.68 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 annualized dividend and a yield of 2.31%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

A number of analysts have recently issued reports on JNJ shares. Jefferies Group raised their price target on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, October 16th. UBS Group restated a “buy” rating and set a $148.00 price target on shares of Johnson & Johnson in a report on Saturday, September 30th. Cowen set a $147.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, October 6th. Citigroup increased their price objective on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Finally, Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price objective for the company in a research report on Wednesday, December 20th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and an average target price of $145.94.

TRADEMARK VIOLATION WARNING: “BTR Capital Management Inc. Has $12.32 Million Holdings in Johnson & Johnson (JNJ)” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2018/01/13/btr-capital-management-inc-has-12-32-million-holdings-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.